Residents of countries such as Italy, the United Kingdom, Canada, Germany, and South Korea receive second-dose Covit-19 vaccines from a variety of manufacturers.
Although there are still some strong studies regarding the strategy, it is pointed out as a way to prevent people from taking the second dose due to the lack of immunizing agents in the vaccine at a specific location.
One of the pioneers in this endeavor is the United Kingdom. The British MHRA (Medical and Health Products Regulatory Agency) emphasizes that studies on immunity (the ability of a vaccine to stimulate immunity) are conducted when different drugs are used.
However, the company acknowledges the possibility of exchanging immune agents.
“Every effort should be made to determine which vaccine the individual received for his or her first dose and to complete the two-dose schedule with the same dose of vaccine. Where unknown, it is reasonable to assume the amount of production available locally to complete the schedule in these circumstances, ”the agency’s technology notes.
Elsewhere in Europe, the reason is another. Countries such as France, Spain and Germany choose the second shot of a different vaccine for those who receive AstraZeneca injections.
Change involves fears Freezing formation in some population groups (rarely considered), Especially those under 60 years of age.
Recently, the President of Germany, Angela Merkel, took the modern scale, After being initially vaccinated with astrogen.
Despite the lack of consensus in the scientific community, the EMA (European Medicines Agency) said last Wednesday (23) that there was a “good scientific basis” for indicating that the combination of vaccines against Govit-19 was safe and effective.
The rationale of the European regulatory body is that the two dose vaccines in use in the block – Pfizer / Bioendech, Moderna and Astrogenega – work similarly on the spike protein of the corona virus.
However, the EMA points out that it is currently “not in a position to make definitive recommendations on the use of different Covit-19 vaccines in two doses”.
Studies conducted in the United Kingdom have already released initial safety data. AstraZeneca and Pfizer vaccines were analyzed.
“The initial reaction and safety data of the com- govi 2 clinical trial showed that test participants who received different vaccines for the first and second dose experienced increased reactions after the second dose compared to those who received the same dose. The chances of experiencing malaise and muscle aches are high, however, and these symptoms are not hospitalized, and the highest part of the increase in rigogenesis is seen within 48 hours of immunization, ”says MHRA.
Part of the study looking at the effect of mixing vaccines on the immune system is expected to be released soon.
In Brazil, the possibility of exchanging vaccines has not yet been considered. According to Isabella Pallal, Vice President, SBIM (Brazilian Society of Immunizations), “There are no credible reasons to start with [vacina] Finish the other one “.
He points out that it is possible from the outset to guarantee that people with the same level of immunosuppressive agent will be vaccinated, and that the distribution tables offer some assurances that this can be maintained.